Intersect ENT shares are trading lower after SVB Leerink downgraded the stock from Outperform to Market Perform and lowered the price target from $41 to $29 following the company report of worse-than-expected Q1 EPS. The company also lowered its FY19 sale
Benzinga Newsdesk